Peptide Insider

PE-22-28 Side Effects: What the Evidence Actually Shows

PE-22-28 side effects — what the evidence actually shows

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

PE-22-28 side effects have never been recorded in a human being. This seven amino-acid peptide, cut down from the antidepressant candidate spadin, exists in the literature as mouse behavior, patch-clamp traces, and cultured cells — nothing else. It is also a potassium-channel blocker, an unusual thing to sell as a wellness compound: TREK-1 blockade is the mechanism, and its consequences outside a mouse brain have never been measured in a person. This page maps what the four published papers report, which findings belong to PE-22-28 and which belong to its relatives, and why every side-effect list attached to it came from elsewhere.

Quick Answer: What the PE-22-28 Side-Effect Data Actually Shows

There is no published human safety data for PE-22-28. No trial, no case series, no adverse-event table. The record is four preclinical papers: the 2017 study that designed PE 22-28 and measured a TREK-1 IC50 of 0.12 nM versus 40-60 nM for spadin (PMID 28955242), a 2019 review of TREK-1 blockers (PMID 30291907), a 2019 mouse stroke study of the analog mini-spadin (PMID 31325429), and a 2021 pancreatic beta-cell study (PMID 33737242). Every one is an animal or cell experiment. Any percentage attached to PE-22-28 tolerability was not measured on this compound. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience: Zero Monitored Humans

On our cagrilintide and eloralintide side-effect pages, this box summarizes what thousands of monitored trial participants went through. For PE-22-28 the honest version is different: no human being has ever taken this peptide under study conditions where side effects were recorded. The documented experience is a mouse in a forced swimming test.

People do take it — research-market vials sell steadily to a mood and anxiety audience. Those experiences are real, and they have never been collected, controlled, or published. For a compound whose mechanism is blocking an ion channel, that gap is the entire safety picture.

When we publish an individual account here, it will be a real person, named with permission — like the reader experience on our anxiety peptides guide. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is PE-22-28?

PE-22-28 is a seven amino-acid peptide designed from the blood degradation products of spadin, an endogenous peptide released from the sortilin propeptide. Spadin, written PE 12-28 in the literature, blocks the TREK-1 potassium channel and showed antidepressant activity in mice — but its activity disappeared beyond 7 h after administration, which sent researchers looking for a sturdier version. PE 22-28 was the result, with better specificity and affinity for TREK-1 than its parent (PMID 28955242). The research market sells it to a mood audience, alongside the compounds in our peptides for anxiety coverage. Everything published about it was measured in mice and cells.

How It’s Thought to Work

PE-22-28 blocks TREK-1, a two-pore-domain potassium channel the depression literature treats as an original target: most antidepressants act on monoamines instead. Measured on hTREK-1/HEK cells with the patch-clamp technique, PE 22-28 displayed better specificity and affinity for the channel than spadin, with an IC50 of 0.12 nM versus 40-60 nM for spadin. Different modifications of its N- or C-terminal ends maintained or abolished TREK-1 channel activity without affecting affinity. In mice it reduced immobility time in the forced swimming test, reduced latency to eat in the novelty suppressed feeding test after a 4-day sub-chronic treatment, induced neurogenesis after only a 4-day treatment, and raised PSD-95 expression in cortical neurons (PMID 28955242).

KEY TAKEAWAY

An IC50 of 0.12 nM is a measurement of how tightly a molecule binds a channel in a dish. It is not a dose, not a safety margin, and not evidence that anything good or bad happens in a person. Potency and tolerability are separate questions, and only one of them has been asked here.

The Entire Evidence Base: Four Preclinical Papers

The 2017 paper is the only one built around PE 22-28 itself: it designed the peptide, measured the TREK-1 IC50, ran the behavioral tests above, and reported an action duration improved to up to 23 h instead of 7 h (PMID 28955242). The 2019 review sets the context: spadin is a 17-amino acid peptide blocking TREK-1, and where fluoxetine requires 3-4 weeks for its antidepressant effect to manifest, spadin acted within only 4 days of treatment, with antidepressant properties associated with increased neurogenesis and synaptogenesis. Shortened analogs, the review concludes, present increased inhibition potency for TREK-1, improved activity, and prolonged bioavailability (PMID 30291907).

The other two papers test relatives, not PE 22-28. A 2019 study injected mini-spadin, described as spadin’s short analog, into mice with focal ischemia and reported protection against stroke damage and post-stroke depression (PMID 31325429). A 2021 study examined sortilin-derived peptides in pancreatic beta cells (PMID 33737242). Neither abstract states that mini-spadin and PE 22-28 are the same molecule, so we do not treat their findings as PE-22-28 findings. Borrowing a relative’s data is an inference, and honest pages label it as one — the rule we apply to AHK-Cu.

The Side-Effect Dataset That Doesn’t Exist

A real side-effect profile needs four things: humans receiving the compound, a control group, systematic recording of everything that happens, and publication. PE-22-28 has none of the four. There is no adverse-event table anywhere in the literature, no heart-rate or blood-pressure data in people, no bloodwork, no discontinuation rate, no maximum tolerated dose. The rodent work measured antidepressant-like behavior and brain plasticity — immobility time, latency to eat, neurogenesis, PSD-95 — because that was the question being asked. Harm was never an endpoint. When we say “no data” we mean it literally, and it cuts both ways: nothing documents harm, and nothing demonstrates safety.

PERSONAL OBSERVATION — PI EDITORIAL

Reading the PE-22-28 listings against the abstracts, one pattern stood out. Vendors describe it as a fast-acting mood peptide with a clean profile, and the “fast-acting” half is traceable — the mouse work really does show effects after a 4-day treatment. The “clean profile” half is attached to nothing at all. Watching a sourced claim and an invented one travel through the same sentence, in the same confident tone, is the most useful thing this compound taught us.

What Blocking a Potassium Channel Means

This is what makes PE-22-28 unusual among research-market peptides: most are signaling molecules, and this one is an ion-channel blocker. Ion channels do not exist solely to set mood. The 2019 review frames TREK-1 as an original target in depression, and notes that fluoxetine — a drug with proven clinical efficacy — is itself among the TREK-1 inhibitors (PMID 30291907). The stroke paper calls TREK-1 a crucial target in the pathogenesis of both stroke and depression (PMID 31325429). What none of the four abstracts provides is a map of where else this channel matters in a human body, or what sustained blockade does there. That question is open, not settled.

The Dose That Flips the Effect

The most safety-relevant finding in this file is not an adverse event. It is a direction change. In the stroke study, electrophysiology showed mini-spadin had a biphasic action on TREK-1: at low doses the channel activity was increased, whereas at higher doses it was inhibited. The researchers used that deliberately, injecting a single low dose of 0.03 µg/kg intraperitoneally 30 min after the onset of ischemia, once a day during 7 days post-ischemia to activate the channel and induce neuroprotection, then a higher concentration of 3 µg/kg once a day for 4 days/week to inhibit it and produce the antidepressant effect (PMID 31325429). A compound whose effect inverts with dose is one where “more” is not a stronger version of the same thing.

Beyond the Brain: The Beta-Cell Findings

The 2021 paper is the clearest evidence that this peptide family acts outside the brain. Working on pancreatic beta cells, researchers found that the sortilin-derived peptide PE and its derivatives — spadin and mini-spadin — raised intracellular calcium by depolarizing the membrane and protected beta cells against death induced by Interleukin-1β, through the CaM-Kinase pathway and phosphorylation of the transcription factor CREB. PE stimulates insulin secretion only in response to glucose, and mini-spadin promoted beta-cell proliferation, which the authors read as a possible regenerative effect (PMID 33737242). Read as pharmacology, that is a family with pancreatic activity. Read as safety data it is nothing: no human glucose or insulin measurement exists.

Route: What the Abstracts Do and Don’t Say

Research-market PE-22-28 arrives as a lyophilized vial to be reconstituted and injected, or as a nasal spray. The published work supports neither route in humans. The stroke study injected mini-spadin intraperitoneally, a route used in rodents and not in people (PMID 31325429); the 2017 paper reports in vivo behavioral results and an improved action duration of up to 23 h without naming a route in its abstract (PMID 28955242). Nobody has published absorption or elimination data for this peptide in a human.

PRACTICAL NOTES — WHAT THE ROUTE DATA DOES AND DOESN’T COVER

  • Intraperitoneal injection in mice has no human equivalent; it is a laboratory convenience
  • An action duration of up to 23 h was measured in animals, not in people
  • No human pharmacokinetic study exists for PE-22-28 by injection or nasal delivery
  • Reconstitution with bacteriostatic water is a sterility question, separate from the evidence question

Why “No Reported Side Effects” Isn’t “No Side Effects”

“No side effects have been reported for PE-22-28” is technically true and structurally empty. Reporting requires machinery: trials with adverse-event logging, a pharmacovigilance system, published case reports. An unapproved compound sold outside medicine has none of it. Someone who injects this peptide and feels wrong tells a forum or tells nobody, and neither reaches a literature search. Absence of evidence reflects absence of surveillance, not surveillance returning a clean result. The same empty sentence appears on our dihexa and humanin pages, for exactly the same reason.

What Users Report: Self-Reported Effects From Reddit

Every paper on this page describes mice or cells, and no human has taken PE-22-28 under observation. We searched Reddit on September 5, 2026, found 72 relevant posts from 2023 to 2026, and read the comment threads of eleven, across r/Peptides, r/anhedonia, r/NooTopics, r/Nootropics, r/PeptideForum and r/BiohackingU. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Nearly everyone posting describes treatment-resistant depression, anxiety, anhedonia or postpartum depression, and several are mid-taper off a prescribed drug, so mood changes have several candidate causes, expectation among them.

The most serious reports describe dissociation that outlasted the peptide. One commenter, naming neither route nor vendor, described intense visual snow and dissociation starting about four hours after a second dose and lasting roughly six months, after a good first two days (r/Peptides). Two later replies, possibly from one person, reported dissociation after about a month of use: one had moved from 200 to 400 mcg and was still dissociating a month after stopping; the other was also taking Semax, blamed the combination, and did better without it.

Three people describe the opposite of an antidepressant effect. One said it left them depressed and flat; another, who had gone in with high hopes, felt better within days of finishing a vial (r/Peptides). A poster who tried it twice reported low mood and energy by day two both times, quitting by day seven and recovering within days (r/anhedonia). A long-term user said it never lowered their mood but had heard of people becoming suddenly depressed on it (r/NooTopics).

Benefit reports outnumber the bad ones, and most describe something subtle. At least a dozen distinct posters say it helped. A user of more than a year described better mood and less brain fog: “it’s not a miracle, it’s subtle” (r/PeptideForum). A postpartum poster on 300 to 600 mcg by nasal spray said it kept postpartum depression manageable with no side effects, while noting her own sleep deprivation (thread); another there credited it with lifting anhedonia they blamed on retatrutide. Others described a steadier mood on 0.18 to 0.24 mg every few days (thread) and sharper short-term memory on 600 mcg a day intranasally (r/Nootropics). One new user felt briefly jittery after one 400 mcg nasal dose (r/Peptides). Three felt little or nothing.

Nearly everyone here is also on, or coming off, a psychiatric drug. Two posters, one on duloxetine and one on citalopram after a bereavement, asked about SSRI or SNRI interactions and got theories, not experience; the citalopram poster was told the peptide is nowhere near the drug’s strength (thread; thread). In the newest thread one satisfied user had kept taking their medications, another was using it while tapering lamotrigine and still in withdrawal, and the original poster planned to taper fluoxetine, itself a TREK-1 blocker per the stacking section above (r/BiohackingU). No report here can separate taper, stack and peptide.

Nobody knows what is in the bottle. Most users mix their own nasal spray from powder; one doses a pre-reconstituted bottle by syringe units without knowing its concentration, which another commenter called concerning (thread). The r/anhedonia thread also hosts a seller working by direct message and a pasted chatbot answer claiming PE-22-28 is tirzepatide. The doses described, 150 mcg to a milligram a day, have no human reference point.

HOW TO READ SELF-REPORTS

Roughly two dozen people describe using PE-22-28; none describes a measurement, only how they felt. Most report a subtle lift, three report flat mood, and at least two report dissociation lasting weeks to months. None of it can be rated for frequency, and every case has a competing explanation: a taper, a stacked peptide, the postpartum period, the hope that brought the poster to the thread. Whether the dose-reversing channel effect described above bears on any of this is unknowable from anonymous accounts of unmeasured products.

Doses: What the Studies Actually Administered

Here is the complete list of doses in these four abstracts. The stroke study gave mini-spadin 0.03 µg/kg intraperitoneally, once a day during 7 days post-ischemia, then 3 µg/kg once a day for 4 days/week (PMID 31325429). That is the whole list — and it belongs to mini-spadin in mice, not to PE 22-28 in humans. The 2017 paper describes a 4-day sub-chronic treatment in mice without stating a quantity in its abstract (PMID 28955242). We report what studies administered and nothing more, so that is where this section ends.

DID YOU KNOW

The only published doses in this family are micrograms per kilogram of mouse, while research vials are sold in milligram quantities. No published work bridges that gap, and the biphasic finding means the gap matters in both directions. Our peptide calculator does reconstitution math and deliberately nothing else.

Stacking PE-22-28: SSRIs and the Missing Studies

The combination people ask about most is PE-22-28 alongside a prescribed antidepressant. The 2019 review notes that fluoxetine is itself among the inhibitors of TREK-1 channels with proven efficacy in the clinic (PMID 30291907). Layering a peptide designed to block the same channel on top of a drug that already does is not neutral, and no published study has tested that combination in any species. Stacks with Selank or the compounds in our brain health and brain function guides are equally unstudied. Uncertainty does not average out when compounds are combined; it multiplies.

Where Rodent Data Stops: The Research-Product Reality

The research-vial problem is usually that the vial does not inherit the trials. Here there are no trials to inherit, so the vial rests on its own documentation. The gap shows up three ways. Identity: a batch-matched COA is the only evidence a vial holds a seven amino-acid peptide of the right sequence. Concentration arithmetic: the buyer does that math against no established human reference dose. No reference point: there is no trial-grade PE-22-28 experience to compare a product against, because that trial was never run. Everything in this channel is sold strictly for non-human research use.

PERSONAL OBSERVATION — PI EDITORIAL

What stayed with us after reading these four papers is how carefully the researchers separated their molecules — PE, spadin, mini-spadin, PE 22-28, each named precisely in every sentence — and how completely the market flattens them into one product name. The distinctions exist because the compounds are not interchangeable. A page that reports mini-spadin’s mouse doses as PE-22-28’s doses has quietly invented data, and we would rather leave a section short.

Sourcing and Verification

With no safety literature, product quality is the only safety variable a buyer can influence, so documentation matters more here, not less. The checklist: a batch-matched COA naming the peptide and quantity, independent third-party testing with a verifiable report number, and skepticism toward any listing that calls a mouse study clinical or prints spadin’s data under a PE-22-28 heading. Sequence identity matters especially for a short peptide whose terminal modifications, in the source paper, could abolish channel activity outright. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews and lab testing explainer cover what passing documentation looks like.

US Regulatory Status

PE-22-28 is not an approved drug and has never been evaluated by the FDA. There is no prescription version; it exists only in the research-chemical channel, sold for non-human research use with no regulatory review of identity, purity, or safety. The research behind it is academic work on TREK-1 as a drug target, published across pharmacology journals — not a development program with a filing behind it, which matters when a listing implies approval is coming. We found no registered human trial that would fill this page’s gaps. If one appears, this section changes first.

Frequently Asked Questions

What are the side effects of PE-22-28?

Unknown. No human study of PE-22-28 has been published, so no side-effect rates exist. The four papers behind it are mouse and cell experiments measuring antidepressant-like behavior, channel blockade, and cell survival. Side-effect lists elsewhere have no source in this compound’s literature.

Has PE-22-28 been tested in humans?

No. Every published experiment used mice, cultured cells, or both. The peptide was designed in 2017 from spadin’s blood degradation products and studied for antidepressant activity in animals; no clinical trial data exists.

Is PE-22-28 safe?

No published data answers that in either direction. Nothing documents harm and nothing demonstrates safety, because the studies were built to measure efficacy in animals. Its mechanism is blockade of the TREK-1 potassium channel, and sustained blockade has never been measured in a person.

Is PE-22-28 the same as spadin or mini-spadin?

No. Spadin is a 17-amino acid peptide, written PE 12-28; PE 22-28 is a seven amino-acid peptide designed from spadin’s degradation products. Mini-spadin is another short analog, and the abstracts do not state that it and PE 22-28 are the same molecule.

What dose did the studies use?

The only doses in these abstracts belong to mini-spadin in mice: 0.03 microgram per kilogram intraperitoneally once a day during 7 days after ischemia, then 3 micrograms per kilogram once a day for 4 days per week. No human dose has ever been established.

How fast does PE-22-28 work?

In mice, effects appeared after a 4-day sub-chronic treatment, and action duration reached up to 23 h versus 7 h for spadin. The related review contrasts that with fluoxetine, which requires 3-4 weeks in patients. All of the PE 22-28 timing figures are animal measurements.

Glossary of Terms

  • PE 22-28: a seven amino-acid peptide designed from spadin’s blood degradation products; a TREK-1 blocker studied in mice.
  • Spadin (PE 12-28): the 17-amino acid parent peptide released from the sortilin propeptide, with antidepressant activity in animals.
  • Mini-spadin: another short spadin analog; the compound tested in the stroke study, not stated to be identical to PE 22-28.
  • TREK-1: a two-pore-domain potassium channel treated here as a target in depression and stroke.
  • IC50: the concentration that produces half-maximum inhibition in a dish; a potency measure, not a dose.
  • Forced swimming test: the rodent assay behind most antidepressant claims for this family; a mouse endpoint.
  • Pharmacovigilance: the surveillance that turns real-world side effects into recorded data; nonexistent for PE-22-28.

References